ClinicalTrials.gg
RecruitingNCT07523399Updated Apr 13, 2026

Joint Health, Balance and Quality of Life in Adults With Hemophilia A

An observational study in Hemophilia A, sponsored by Yuzuncu Yil University. Recruiting at 1 site in Turkey (Türkiye). Open to male participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-04-13.

Sponsored by Yuzuncu Yil University · Observational

From the registry’s dates

  • Primary completion was expected by Apr 2026, 6 months ago, but the record still lists the study as recruiting.
  • Started Feb 2026; still recruiting 8 months later.
Study type
Observational
Model
Case-only
Time perspective
Cross-sectional
Enrollment
36
Ages
18 Years to 65 Years
Sex
Male
01

Study summary

Hemophilia is a hereditary bleeding disorder characterized by recurrent bleeding episodes, particularly into joints and muscles, leading to chronic musculoskeletal complications. Repeated joint bleeding may result in hemophilic arthropathy, which is associated with progressive joint damage, chronic pain, reduced mobility, and functional limitations. Advances in prophylactic treatment have significantly improved life expectancy in individuals with hemophilia; however, long-term musculoskeletal complications continue to affect daily functioning and overall well-being. Therefore, the evaluation of health-related quality of life (QoL) has become increasingly important in adults with hemophilia, as it reflects the broader impact of the disease beyond clinical severity.

Joint health is considered one of the major determinants of physical functioning in people with hemophilia. Hemophilic arthropathy may lead to chronic pain, muscle weakness, reduced range of motion, and impaired physical performance. In addition to structural joint changes, impairments in neuromuscular function, including reduced proprioception, muscle strength, and postural control, may also contribute to activity limitations. Balance impairments may increase the risk of falls, which may be particularly relevant for individuals with hemophilia because fall-related trauma can lead to bleeding episodes and further joint deterioration. Although previous studies have investigated the relationship between joint health, pain, and functional limitations, the combined contribution of joint health, pain severity, dynamic balance performance, and fall history to QoL in adults with hemophilia has not been sufficiently clarified.

This prospective cross-sectional study aims to evaluate QoL in adults with hemophilia and to investigate the associations of joint health, pain severity, dynamic balance performance, and fall history with QoL outcomes. The study includes 36 adults diagnosed with severe hemophilia A who are followed at the Adult Hematology Unit of Van Yuzuncu Yil University. Participants aged 18 years and older who met the inclusion criteria were recruited consecutively. Individuals using walking aids, having neurological or psychiatric disorders, chronic inflammatory diseases, recent lower extremity surgery, or regular medication use that could affect balance were excluded.

Joint health is assessed using the Hemophilia Joint Health Score (HJHS), a clinician-administered tool evaluating joint impairment in the knees and ankles. Dynamic balance is assessed using a computerized stabilometric platform (Pro-kin Tecnobody Stabilometric Analysis System) with the Limits of Stability (LoS) test, which evaluates the ability to voluntarily control the center of pressure within the base of support. Pain intensity is measured using the Numeric Pain Rating Scale (NPRS), an 11-point scale ranging from 0 to 10. Fall history is determined based on the self-reported number of falls within the previous 12 months. QoL is assessed using the Turkish version of the Haemophilia-Specific Quality of Life Questionnaire for adults (Haem-A-QoL), a validated patient-reported outcome measure evaluating multiple domains of physical, emotional, and social well-being. Higher scores indicate poorer QoL.

The findings of this study are expected to improve the understanding of factors associated with QoL in adults with hemophilia and may help identify potentially modifiable clinical targets for rehabilitation interventions.

02

Conditions studied

  • Hemophilia A

Keywords

  • Quality of life
  • Hemophilia A
  • Arthropathy
  • Postural balance
  • Falls
  • Musculoskeletal Pain
03

In context

Hemophilia A

844 studies on the registry are indexed under Hemophilia A; 138 are open to participants now.

This study's planned enrollment of 36 is below the median of 81 across 310 observational studies indexed under Hemophilia A.

Browse Hemophilia A studies →

Lead sponsor

Yuzuncu Yil University is the lead sponsor of 78 studies on the registry; 20 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
Male
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adults with hemophilia A

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of severe hemophilia A
  • Age ≥18 years
  • A minimum single-joint score of 3 points for the knee or ankle according to the Hemophilia Joint Health Score (HJHS)

Exclusion criteria

Exclusion Criteria:

  • Use of walking aids (e.g., crutches)
  • Presence of neurological or psychiatric disorders, chronic inflammatory disease, -Regular use of medications that could affect balance,
  • History of major lower extremity surgery within the previous six months.
05

Study design

Observational model
Case-only
Time perspective
Cross-sectional
Enrollment
36 participants (estimated)
Target follow-up
2 Weeks
Patient registry
Yes

Groups and cohorts

  • Hemophilia A
06

What researchers measure

Primary outcomes

  1. Health-related quality of life

    Health-related quality of life will be assessed using the Haemophilia-Specific Quality of Life Questionnaire for Adults (Haem-A-QoL). The total score ranges from 0 to 100, with higher scores indicating poorer quality of life.

    Time frame: Baseline

  2. Joint Health

    Joint health will be evaluated using the Hemophilia Joint Health Score (HJHS). Higher scores indicate poorer joint health status.

    Time frame: Baseline

  3. Postural Balance

    Dynamic postural balance were evaluated with the Pro-kin Technobody Posturographic Platform (Pro-kin 212, Technobody s.r.l, Dalmine, 21044 Bergamo, Italy).

    Time frame: Baseline

Secondary outcomes

  1. Musculoskeletal Pain

    Pain severity will be measured using the Numeric Pain Rating Scale (NPRS), ranging from 0 (no pain) to 10 (worst possible pain).

    Time frame: Baseline

  2. Falls

    Fall history will be assessed as the self-reported number of falls experienced within the previous 12 months.

    Time frame: Baseline

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2026 (actual). Primary completion is estimated for Apr 2026, 2 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 4, 2026
First posted
Apr 13, 2026
StartActual
Feb 21, 2026
Primary completionEst.
Apr 21, 2026
CompletionEst.
May 21, 2026
Last update
Apr 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07523399
Lead sponsor
Yuzuncu Yil University
Responsible party
Ayse Merve TAT (Assistant Professor, Yuzuncu Yil University) — Principal investigator
First posted
Apr 13, 2026
Start date
Feb 21, 2026
Primary completion
Apr 21, 2026 (estimated)
Completion
May 21, 2026 (estimated)
Last update
Apr 13, 2026

Study contacts

Ayse Merve Tat, Assistant Professor
Contact
aysemervetat@yyu.edu.tr
+905052431112

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion